Radiolabeling and in vitro /in vivo evaluation of N-(1-adamantyl)-8- methoxy-4-oxo-1-phenyl-1,4-dihydroquinoline-3-carboxamide as a PET probe for imaging cannabinoid type 2 receptor

Journal of Neurochemistry

Volumn 126, Issue 5, 2013, Pages 616-624

  Mu, Linjing ^a   Bieri, Daniel ^b   Slavik, Roger ^b   Drandarov, Konstantin ^a   Müller, Adrienne ^b   Čermak, Stjepko ^b,d   Weber, Markus ^c   Schibli, Roger ^a,b   Krämer, Stefanie D ^b   Ametamey, Simon M ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b ETH ZURICH   (Switzerland)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^d RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

autoradiography; cannabinoid receptor type 2 ligand; neurodegeneration; radiolabeling; small animal PET

Indexed keywords

1 (2,3 DICHLOROBENZOYL) 5 METHOXY 2 METHYL 3 (2 MORPHOLINOETHYL)INDOLE; CANNABINOID 2 RECEPTOR; MULTIDRUG RESISTANCE PROTEIN; N (1 ADAMANTYL) 8 METHOXY 4 OXO 1 PHENYL 1,4 DIHYDROQUINOLINE 3 CARBOXAMIDE; TRACER; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BLOOD BRAIN BARRIER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MDCK CELL; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOCHEMISTRY; RAT; RECEPTOR BINDING; SPINAL CORD; SPLEEN; WISTAR RAT;

AUTORADIOGRAPHY; CANNABINOID RECEPTOR TYPE 2 LIGAND; NEURODEGENERATION; RADIOLABELING; SMALL-ANIMAL PET;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; AUTORADIOGRAPHY; BINDING, COMPETITIVE; BLOOD PROTEINS; BRAIN; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INDICATORS AND REAGENTS; INDOLES; ISOTOPE LABELING; MALE; MICE; MORPHOLINES; P-GLYCOPROTEINS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB2;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 84883143252     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12354     Document Type: Article

References (47)

1. Ahmad R., Koole M., Evens N., Serdons K., Verbruggen A., Bormans G., and, Van Laere K., (2013) Whole-body biodistribution and radiation dosimetry of the cannabinoid type 2 receptor ligand [C]-NE40 in healthy subjects. Mol. Imaging Biol. [Epub ahead of print].
2. Ashton J. C., and, Glass M., (2007) The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr. Neuropharmacol. 5, 73-80.
3. Bakos E., Evers R., Szakacs G., et al,. (1998) Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain. J. Biol. Chem. 273, 32167-32175.
4. Baumann C. A., Mu L., Johannsen S., Honer M., Schubiger P. A., and, Ametamey S. M., (2010) Structure-activity relationships of fluorinated (E)-3-((6-methylpyridin-2-yl)ethynyl)cyclohex-2-enone-O-methyloxime (ABP688) derivatives and the discovery of a high affinity analogue as a potential candidate for imaging metabotropic glutamate recepors subtype 5 (mGluR5) with positron emission tomography (PET). J. Med. Chem. 53, 4009-4017.
5. Benito C., Nunez E., Pazos M. R., Tolon R. M., and, Romero J., (2007a) The endocannabinoid system and Alzheimer's disease. Mol. Neurobiol. 36, 75-81.
6. Benito C., Romero J. P., Tolon R. M., Clemente D., Docagne F., Hillard C. J., Guaza C., and, Romero J., (2007b) Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J. Neurosci. 27, 2396-2402.
7. Console-Bram L., Marcu J., and, Abood M. E., (2012) Cannabinoid receptors: nomenclature and pharmacological principles. Prog. Neuropsychopharmacol. Biol. Psychiatry 38, 4-15.
8. Dishino D. D., Welch M. J., Kilbourn M. R., and, Raichle M. E., (1983) Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. J. Nucl. Med. 24, 1030-1038.
9. Evens N., and, Bormans G. M., (2010) Non-invasive imaging of the type 2 cannabinoid receptor, focus on positron emission tomography. Curr. Top. Med. Chem. 10, 1527-1543.
10. Evens N., Vandeputte C., Muccioli G. G., Lambert D. M., Baekelandt V., Verbruggen A. M., Debyser Z., Van Laere K., and, Bormans G. M., (2011) Synthesis, in vitro and in vivo evaluation of fluorine-18 labelled FE-GW405833 as a PET tracer for type 2 cannabinoid receptor imaging. Bioorg. Med. Chem. 19, 4499-4505.
11. Fernandez-Ruiz J., Romero J., Velasco G., Tolon R. M., Ramos J. A., and, Guzman M., (2007) Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol. Sci. 28, 39-45.
12. Fujinaga M., Kumata K., Yanamoto K., et al,. (2010) Radiosynthesis of novel carbon-11-labeled triaryl ligands for cannabinoid-type 2 receptor. Bioorg. Med. Chem. Lett. 20, 1565-1568.
13. Galiegue S., Mary S., Marchand J., et al,. (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232, 54-61.
14. Gong J. P., Onaivi E. S., Ishiguro H., Liu Q. R., Tagliaferro P. A., Brusco A., and, Uhl G. R., (2006) Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res. 1071, 10-23.
15. Hammerle S. P., Rothen-Rutishauser B., Kramer S. D., Gunthert M., and, Wunderli-Allenspach H., (2000) P-Glycoprotein in cell cultures: a combined approach to study expression, localisation, and functionality in the confocal microscope. Eur. J. Pharm. Sci. 12, 69-77.
16. Hohmann A. G., and, Herkenham M., (1999) Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience 90, 923-931.
17. Honer M., Bruhlmeier M., Missimer J., Schubiger A. P., and, Ametamey S. M., (2004) Dynamic imaging of striatal D2 receptors in mice using quad-HIDAC PET. J. Nucl. Med. 45, 464-470.
18. Horti A. G., and, Van Laere K., (2008) Development of radioligands for in vivo imaging of type 1 cannabinoid receptors (CB1) in human brain. Curr. Pharm. Des. 14, 3363-3383.
19. Horti A. G., Gao Y., Ravert H. T., Finley P., Valentine H., Wong D. F., Endres C. J., Savonenko A. V., and, Dannals R. F., (2010) Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2). Bioorg. Med. Chem. 18, 5202-5207.
20. Kiferle L., Politis M., Muraro P. A., and, Piccini P., (2011) Positron emission tomography imaging in multiple sclerosis-current status and future applications. Eur. J. Neurol. 18, 226-231.
21. Matsuda L. A., Lolait S. J., Brownstein M. J., Young A. C., and, Bonner T. I., (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564.
22. Milicevic Sephton S., Mu L., Schweizer W. B., Schibli R., Kramer S. D., and, Ametamey S. M., (2012) Synthesis and evaluation of novel alpha-fluorinated (E)-3-((6-methylpyridin-2-yl)ethynyl)cyclohex-2-enone-O-methyl oxime (ABP688) derivatives as metabotropic glutamate receptor subtype 5 PET radiotracers. J. Med. Chem. 55, 7154-7162.
23. Muccioli G. G., and, Lambert D. M., (2006) Latest advances in cannabinoid receptor antagonists and inverse agonists. Expert Opin. Ther. Pat. 16, 1405-1423.
24. Munro S., Thomas K. L., and, Abu-Shaar M., (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65.
25. Onaivi E. S., (2009) Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications. Int. Rev. Neurobiol. 88, 335-369.
26. Pasquini S., De Rosa M., Pedani V., et al,. (2011) Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice. J. Med. Chem. 54, 5444-5453.
27. Pertwee R. G., (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74, 129-180.
28. Pertwee R. G., (2009) Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br. J. Pharmacol. 156, 397-411.
29. Price T. J., Helesic G., Parghi D., Hargreaves K. M., and, Flores C. M., (2003) The neuronal distribution of cannabinoid receptor type 1 in the trigeminal ganglion of the rat. Neuroscience 120, 155-162.
30. Ramirez S. H., Hasko J., Skuba A., et al,. (2012) Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions. J. Neurosci. 32, 4004-4016.
31. Rom S., and, Persidsky Y., (2013) Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation. J. Neuroimmune Pharmacol. 8, 608-620.
32. Rossi S., Bernardi G., and, Centonze D., (2010) The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis. Exp. Neurol. 224, 92-102.
33. Ruhl T., Deuther-Conrad W., Fischer S., Gunther R., Hennig L., Krautscheid H., and, Brust P., (2012) Cannabinoid receptor type 2 (CB2)-selective N-aryl-oxadiazolyl-propionamides: synthesis, radiolabelling, molecular modelling and biological evaluation. Org. Med. Chem. Lett. 2, 32.
34. Schatz A. R., Lee M., Condie R. B., Pulaski J. T., and, Kaminski N. E., (1997) Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol. Appl. Pharmacol. 142, 278-287.
35. Shoemaker J. L., Seely K. A., Reed R. L., Crow J. P., and, Prather P. L., (2007) The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J. Neurochem. 101, 87-98.
36. Sugiura T., and, Waku K., (2002) Cannabinoid receptors and their endogenous ligands. J. Biochem. 132, 7-12.
37. Terry G. E., Hirvonen J., Liow J. S., et al,. (2010) Imaging and quantitation of cannabinoid CB1 receptors in human and monkey brains using (18)F-labeled inverse agonist radioligands. J. Nucl. Med. 51, 112-120.
38. Thomas B. F., Gilliam A. F., Burch D. F., Roche M. J., and, Seltzman H. H., (1998) Comparative receptor binding analyses of cannabinoid agonists and antagonists. J. Pharmacol. Exp. Ther. 285, 285-292.
39. Turkman N., Shavrin A., Ivanov R. A., Rabinovich B., Volgin A., Gelovani J. G., and, Alauddin M. M., (2011) Fluorinated cannabinoid CB2 receptor ligands: synthesis and in vitro binding characteristics of 2-oxoquinoline derivatives. Bioorg. Med. Chem. 19, 5698-5707.
40. Turkman N., Shavrin A., Paolillo V., et al,. (2012) Synthesis and preliminary evaluation of [18F]-labeled 2-oxoquinoline derivatives for PET imaging of cannabinoid CB2 receptor. Nucl. Med. Biol. 39, 593-600.
41. Van Laere K., (2007) In vivo imaging of the endocannabinoid system: a novel window to a central modulatory mechanism in humans. Eur. J. Nucl. Med. Mol. Imaging 34, 1719-1726.
42. Van Laere K., Goffin K., Casteels C., Dupont P., Mortelmans L., de Hoon J., and, Bormans G., (2008) Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [(18)F]MK-9470 PET. Neuroimage 39, 1533-1541.
43. Van Sickle M. D., Duncan M., Kingsley P. J., et al,. (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310, 329-332.
44. Wang Y., Seidel J., Tsui B. M., Vaquero J. J., and, Pomper M. G., (2006) Performance evaluation of the GE healthcare eXplore VISTA dual-ring small-animal PET scanner. J. Nucl. Med. 47, 1891-1900.
45. Wanger-Baumann C. A., Mu L., Honer M., Belli S., Alf M. F., Schubiger P. A., Kramer S. D., and, Ametamey S. M., (2011) In vitro and in vivo evaluation of [F-18]-FDEGPECO as a PET tracer for imaging the metabotropic glutamate receptor subtype 5 (mGluR5). Neuroimage 56, 984-991.
46. Wilson A. A., Jin L., Garcia A., DaSilva J. N., and, Houle S., (2001) An admonition when measuring the lipophilicity of radiotracers using counting techniques. Appl. Radiat. Isot. 54, 203-208.
47. Yiangou Y., Facer P., Durrenberger P., Chessell I. P., Naylor A., Bountra C., Banati R. R., and, Anand P., (2006) COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 6, 12.